5 January 2026 - Idorsia announces that Health Canada has granted marketing authorisation for Jeraygo (aprocitentan) for the treatment of resistant hypertension in adult patients in combination with at least three antihypertensive medicinal products.

Jeraygo is a new oral antihypertensive therapy – the first systemic hypertension treatment to target a new pathway in over 30 years.

Read Idorsia press release